In a first-of-its-kind tie up, Asia’s largest diabetes organisation RSSDI has partnered with Wellthy Therapeutics to pioneer the adoption of diabetes digital therapeutics in India. The #WeDiDiT (Wellthy Digital Diabetes Therapy) trial is all set to prove the efficacy of its 16-week structured diabetes management through a mobile app. The outcome of this multi-center randomized control trial will be measured by the HbA1C levels of patients before and after. Abhishek Shah, the co-founder and CEO of Wellthy Therapeutics re-affirmed the company’s commitment to solve the ‘diabetes epidemic’ and said that even though a clinical trial on a mobile app was unprecedented, he was extremely optimistic about the study’s outcome. He said: “The Wellthy Diabetes intervention is an innovation born out of India, for Indians and South Asians.

Source: dna November 16, 2017 13:41 UTC